Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of TAR-200 vs Intravesical Chemotherapy in High-risk Non-muscle-invasive Bladder Cancer after BCG
2023-507685-10-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of gemcitabine-releasing intravesical system in non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Disease-free survival (DFS). Planned start May 2024; status: authorised.
02
Drugs
gemcitabine-releasing intravesical system
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on 2023-507685-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507685-10-00.